Clinical trials
Relapsed or Refractory B-cell Lymphoma clinical trials
Below are recruiting relapsed or refractory b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,718 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06658951Recruiting
HER2-targeted CAR-T cell therapy for advanced solid tumors
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
Zhengzhou, HenanAges 18–70 - NCT06646497RecruitingPhase 2
Stem cell transplant for tough aplastic anemia in adults 40-60
This study is testing whether a stem cell transplant (from a matched relative, unrelated donor, or half-matched donor) can help adults aged 40–60 with severe aplastic anemia that didn't get better or came back after standard treatments.
Paris, FranceAges 40–60 - NCT04598399Recruiting
Mindfulness program for alcohol relapse prevention
This study compares two non-medication programs to help people with alcohol use disorder stay away from relapse. It tests whether mindfulness-based relapse prevention works better than relaxation meditation without a guide.
AngersAges 18 years+ - NCT06607549RecruitingPhase 1
Targeted drug combo after focused radiation for CNS lymphoma
This trial tests a combination of two targeted drugs (loncastuximab tesirine and rituximab) given after focused radiation (SRS) for people with CNS lymphoma that has come back or not responded to treatment, or who cannot get standard high-dose methotrexate. The goal is to see if this approach is safe and effective.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06592703RecruitingPhase 1
Stem cells for primary progressive MS
This study tests whether stem cells from donated fat tissue can slow down primary progressive multiple sclerosis. You would receive a single injection of the cells into your spinal fluid and be followed for up to 2 years.
CréteilAges 18–55 - NCT06599580Recruiting
Checking kids' arm measurements to prevent relapse after malnutrition recovery
This study tests whether measuring a caregiver's arm width can help predict if a child who recently recovered from severe malnutrition will become malnourished again. It aims to find ways to catch problems early and keep children healthy.
NounaAges 6 months–4.5 years - NCT06569680RecruitingPhase 2
Mosunetuzumab for untreated extranodal marginal zone lymphoma
This trial tests a new drug called mosunetuzumab for people with a type of slow-growing lymphoma (extranodal marginal zone lymphoma) that has not been treated before. The goal is to see if the drug helps shrink the lymphoma and control the disease.
Miami, FloridaAges 18 years+ - NCT06582745RecruitingPhase 2
Trametinib for Langerhans cell histiocytosis (LCH)
This trial tests a targeted drug called trametinib (a MEK inhibitor) for people with Langerhans cell histiocytosis (LCH) that is newly diagnosed, relapsed, or hasn't responded to other treatments. It aims to see if trametinib can better control the disease with fewer side effects.
Fort Worth, TexasAges 1–30 - NCT06464679RecruitingPhase 1
CD19 CAR NK cells for autoimmune diseases
This trial tests a new type of immune cell therapy (CD19 CAR NK cells) for people with certain autoimmune diseases that have not responded to standard treatments. The goal is to see if these cells can safely reduce disease activity.
ShanghaiAges 18–65 - NCT06564324RecruitingPhase 3
Comparing taletrectinib to standard therapy for ROS1-positive lung cancer
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
Hefei, AnhuiAges 18 years+ - NCT06552416RecruitingPhase 1
Safety study of MT-401-OTS for relapsed AML or MDS
This trial tests a new cell therapy called MT-401-OTS for people aged 65 or older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The goal is to see if this treatment is safe and to find the right dose.
Duarte, CaliforniaAges 65 years+ - NCT06563505RecruitingPhase 2
Study of mosunetuzumab plus zanubrutinib for relapsed marginal zone lymphoma
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
Houston, TexasAges 18 years+ - NCT06553053Recruiting
Acupuncture to prevent Crohn's disease relapse
This trial tests if acupuncture can help people with Crohn's disease stay in remission longer and avoid flare-ups. If you are in remission but have had frequent relapses, this study may be for you.
ShanghaiAges 16–75 - NCT06541002Recruiting
SHIFT app for stem cell transplant survivors' sexual health
This trial tests a mobile app (SHIFT) designed to help people who have had a stem cell transplant and are experiencing sexual health concerns. It aims to see if the app can improve your well-being.
Coral Gables, FloridaAges 18 years+ - NCT06469190RecruitingEarly Phase 1
CAR NK cells for treatment-resistant kidney disease
This trial is testing a new therapy made from your own immune cells (called CAR NK cells) that are designed to fight a type of kidney disease that hasn't responded to standard treatments. It may be an option if you have membranous nephropathy, IgA nephropathy, or ANCA-associated vasculitis and previous treatments have failed.
ShanghaiAges 18–70 - NCT06461988RecruitingPhase 2
Talquetamab and lenalidomide after stem cell transplant for myeloma
This trial tests combining two drugs, talquetamab and lenalidomide, as maintenance therapy after a stem cell transplant for multiple myeloma. The goal is to see if this combination helps keep the cancer from coming back.
Palo Alto, CaliforniaAges 18 years+ - NCT06082102RecruitingPhase 3
Comparing orelabrutinib and lenalidomide with rituximab for MZL
This study tests two different drug combinations for people with marginal zone lymphoma that has come back or stopped responding to previous treatment. One group gets orelabrutinib plus rituximab, and the other gets lenalidomide plus rituximab, to see which works better and has fewer side effects.
Bengbu, AuhuiAges 18 years+ - NCT06431633RecruitingPhase 3
Sacituzumab and zimberelimab for lung cancer after surgery
This trial tests a combination of two drugs (sacituzumab and zimberelimab) for people with non-small cell lung cancer that was confined to the chest, was surgically removed, but not completely cleared by prior chemotherapy and immunotherapy. The goal is to see if this treatment can help prevent the cancer from coming back.
Alicante, AlicanteAges 18 years+ - NCT06433752Recruiting
Study of BRIUMVI for relapsing multiple sclerosis
This study looks at how well BRIUMVI (a medicine for relapsing multiple sclerosis) works for people in everyday life. Researchers want to see how people do when they first start the medication.
Birmingham, AlabamaAges 18 years+ - NCT06408259RecruitingPhase 3
Comparing ozanimod and fingolimod for children with MS
This study compares two oral medications, ozanimod and fingolimod, to see which one works better and is safer for children and teenagers with relapsing-remitting MS. Both drugs help reduce MS attacks and slow down the disease.
Loma Linda, CaliforniaAges 10–17 - NCT06383572RecruitingPhase 1/Phase 2
Modified immune cells for blood cancers after chemo
This trial tests a new type of immune cell (NK cell) that has been engineered to target a protein called PRAME found on some cancer cells. It is for people with certain types of blood cancer (AML, MDS, or CMML) that have come back or not responded to treatment.
Houston, TexasAges 18–80 - NCT06343792RecruitingPhase 2
Testing RLS-0071 for steroid-resistant acute graft-versus-host disease
This trial tests a new drug, RLS-0071, for people who are hospitalized with acute graft-versus-host disease that hasn't improved with steroids. It aims to see if the drug is safe and can help control the condition.
Duarte, CaliforniaAges 12 years+ - NCT06287944RecruitingPhase 1
Targeted radiation and chemo before donor stem cell transplant
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
Duarte, CaliforniaAges 18–70 - NCT06252792Recruiting
Daratumumab-pomalidomide-dexamethasone for first-relapse myeloma
This trial tests a combination of three drugs (daratumumab, pomalidomide, and dexamethasone) for people whose multiple myeloma has returned for the first time after initial treatment with RVD. The goal is to see if this new combination can control the cancer.
Changchun, JilinAges 18 years+
Hear when a new Relapsed or Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell lymphoma?
- Yes. Clin2 currently lists 1,718 recruiting relapsed or refractory b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed or Refractory Large B-cell Lymphoma
- Relapsed or Refractory Peripheral T Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.